Griffin Health is proud to announce the expansion of its Positron Emission Tomography (PET) imaging capabilities to include Vizamyl, a breakthrough tool in dementia diagnosis.
Vizamyl (flutemetamol F18 injection) is an FDA-approved radiopharmaceutical agent used in PET scans to visualize beta-amyloid neuritic plaques in the brains of adult patients. The presence of these plaques is a critical biomarker in the diagnosis of Alzheimer’s disease. With the integration of Vizamyl into its imaging portfolio, Griffin is equipped to assist neurologists, geriatricians, and referring physicians in the complex process of dementia diagnosis and treatment planning.
“The availability of Vizamyl PET imaging represents a significant step forward in Griffin Health’s commitment to providing comprehensive, state-of-the-art diagnostic tools for cognitive health,” said Griffin Health Vice President of Diagnostic and Cancer Services Christine Cooper, MS, CNMT, RT(N), RSO, FACHE, FAB. “Early and accurate diagnosis is key to effective patient care, and this expansion ensures our facility is aligned with the most current standards in neuroimaging.”
Vizamyl PET imaging is particularly valuable in cases where the cause of cognitive decline is uncertain, or where a definitive diagnosis would guide clinical decision-making. The scan results can provide additional information to either support or rule out the presence of Alzheimer’s pathology, contributing to a more informed and confident diagnosis.
Griffin offers a comprehensive approach to support neurology patients and their families, including affiliated neurologists (for indicated treatments), physical and occupational therapy, primary care, support groups, and community resources.
For more information about Vizamyl PET, call 203-732-7265 or visit www.griffinhealth.org/vizamyl. Healthcare providers can schedule Vizamyl PET scans for eligible patients by faxing orders to Central Scheduling at Griffin Health at 203-732-1559.